Cerebrolysin
Cerebrolysin is the undisputed apex of neuro-regenerative pharmacology—a highly concentrated, biologically active peptide mixture derived directly from purified porcine brain tissue. Clinically approved across 40+ nations, it is administered via massive volume intramuscular (IM) or intravenous (IV) protocols to treat catastrophic ischemic strokes, severe Traumatic Brain Injuries (TBI), and profound dementia. It does not merely boost focus; it forces actual physical neurogenesis, permanently rebuilding shattered neural networks and profoundly accelerating trauma recovery.
Quick Stats
Scientific Data
Mechanism of Action
Cerebrolysin is a porcine brain-derived peptide preparation containing low-molecular-weight neuropeptides and free amino acids, produced by controlled enzymatic proteolysis of lipid-free porcine brain proteins. It contains neurotrophic factors analogous to BDNF, CNTF, and GDNF.
Cerebrolysin promotes neurogenesis, synaptogenesis, neuronal survival, and recovery from ischemic damage via multimodal neurotrophic factor signaling. It is approved in 40+ countries for stroke, TBI, Alzheimer's disease, and vascular dementia.
Source: PMID: 21281685
Background & History
Cerebrolysin is a neuropeptide preparation derived from purified porcine brain proteins (primarily neocortex), developed in Austria in 1949 by Ernst Ebewe. It contains a mixture of short peptides and free amino acids replicating the neurotrophic factor profile of BDNF, NGF, GDNF, IGF-1, and CNTF. Unlike recombinant growth factors that cannot cross the blood-brain barrier, Cerebrolysin's small peptide fragments do penetrate CNS tissue. It is approved in 41 countries for stroke, TBI, and dementia, with over 100 clinical trials and 40+ years of clinical use history.
Research Use Cases
- ✓Acute and chronic stroke rehabilitation (approved in 41 countries)
- ✓Traumatic brain injury (TBI) recovery
- ✓Alzheimer's disease and vascular dementia (neuroprotection)
- ✓Post-COVID cognitive impairment ("brain fog")
- ✓Performance nootropic: memory, processing speed, neuroplasticity
Dosing Protocol
| Typical Dose | 5-30 mL/day (IV/IM) |
| Frequency | 1× daily for 10-20 days |
| Half-Life | ~2-4 hours (peptide mix) |
Dosing Protocols
Cognitive Enhancement / Nootropic
TBI / Stroke Recovery
Administration
Expected Timeline
Who Is It For?
Cognitive Enhancement / Nootropic
ModerateEuropean approval as nootropic in several countries. Large user base with reported cognitive benefits.
Stroke / TBI Recovery
ModerateApproved in 40+ countries for neurological rehabilitation. Multiple RCTs in stroke recovery.
Alzheimer's Disease
ModerateMultiple clinical trials showing cognitive stabilization or improvement in Alzheimer's patients.
Safety & Considerations
Approved in 40+ countries. Administered IV or IM ONLY — NOT subcutaneous. Generally well-tolerated. May cause headache, dizziness, or injection site reactions. Contraindicated in severe renal impairment and status epilepticus.
Regulatory & Legal Status
Approved in 40+ countries for neurological indications; not FDA-approved in the US
Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Interactions & Contraindications
Do not mix with 5-HT containing solutions or balanced amino acid infusions. Rare: CNS stimulatory effects — reduce dose if severe sleep disruption occurs. Anti-epileptic drugs: monitor seizure threshold (both Cerebrolysin and some anti-epileptics lower threshold). Anti-MAO drugs: potential interaction with aminergic components.
Synergies & Common Stacks
Cerebrolysin provides the neurotrophic factors (BDNF-like activity); Dihexa promotes the synaptogenesis HGF/MET pathway to build the synaptic connections those factors support.
Semax upregulates endogenous BDNF; Cerebrolysin delivers exogenous BDNF-like peptides. Together they comprehensively support neural repair and plasticity from multiple angles.
Dosing Quick Reference
Frequently Asked Questions
Is Cerebrolysin available in the US?▼
How is Cerebrolysin administered?▼
References
- Chen CC et al. “"Cerebrolysin in stroke: a systematic review".” Brain Sciences (2020). PMID: 33286506
Looking for a trusted source? See our recommended suppliers →
Independently tested · COA-verified · Save 10% with our exclusive code